🇺🇸 Transdermal delivery system in United States

217 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Application Site Erythema — 41 reports (18.89%)
  2. Application Site Pruritus — 35 reports (16.13%)
  3. Off Label Use — 26 reports (11.98%)
  4. Headache — 21 reports (9.68%)
  5. Application Site Pain — 19 reports (8.76%)
  6. Product Adhesion Issue — 18 reports (8.29%)
  7. Application Site Rash — 17 reports (7.83%)
  8. Wrong Technique In Product Usage Process — 16 reports (7.37%)
  9. Drug Ineffective — 12 reports (5.53%)
  10. Product Quality Issue — 12 reports (5.53%)

Source database →

Transdermal delivery system in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Transdermal delivery system approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Transdermal delivery system in United States?

Mundipharma AB is the originator. The local marketing authorisation holder may differ — check the official source linked above.